Form 4: Elicio Therapeutics Grants Equity to CFO Preetam Shah

Elicio Therapeutics, Inc. granted 24,000 restricted stock units and 47,900 stock options to Chief Strategy and Financial Officer Preetam Shah.

Summary

• Preetam Shah, the Chief Strategy and Financial Officer of Elicio Therapeutics, Inc. (ELTX), acquired 24,000 Restricted Stock Units (RSUs) and 47,900 Stock Options on February 2, 2026.
• The 24,000 RSUs were acquired at a price of $0 and represent the right to receive one share of common stock per unit.
• The 47,900 Stock Options have an exercise price of $8.1 per share and an expiration date of February 2, 2036.
• Both the RSUs and Stock Options will vest as to 25% on February 2, 2027, the first anniversary of the grant date.
• The remaining RSUs will vest in annual installments over a three-year period thereafter, subject to continued service.
• The remaining Stock Options will vest in monthly installments over a three-year period thereafter, subject to continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for executive alignment and retention, as equity grants incentivize long-term performance and commitment from key management personnel.

Positives

• The grant of restricted stock units and stock options to the Chief Strategy and Financial Officer aligns management's long-term interests with those of shareholders, incentivizing sustained performance.
• Equity compensation is a standard practice for attracting and retaining key executive talent in the biotechnology sector.

Future Outlook

The vesting schedules for the granted RSUs and stock options extend several years into the future, indicating a long-term incentive structure tied to the reporting person's continued service and the company's performance.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are a standard and widely adopted compensation practice within the biotechnology and pharmaceutical industries. These grants are crucial for attracting, retaining, and motivating key executives by aligning their financial interests with the long-term success and shareholder value creation of the company.

Stakeholder Impact

• Shareholders: The equity grant aligns the Chief Strategy and Financial Officer's interests with shareholders, potentially leading to more focused long-term value creation.
• Employees (Reporting Person): The grant provides significant long-term incentive compensation, enhancing retention and motivation.

Next Steps

• Preetam Shah's continued service to Elicio Therapeutics, Inc. is required for the vesting of the granted RSUs and stock options.
• The stock options will become exercisable according to their vesting schedule and can be exercised up to their expiration date of February 2, 2036.

Key Dates

Recommendation

The equity grant to a key executive, the Chief Strategy and Financial Officer, aligns management's long-term interests with shareholders through performance-based vesting. While positive for corporate governance and retention, this routine compensation event alone does not provide sufficient new information to alter a fundamental investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Elicio Therapeutics, ELTX, Preetam Shah, Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, Executive Compensation